Universal Vision (Taiwan) Performance
| 3218 Stock | TWD 215.50 5.00 2.38% |
The entity has a beta of 0.54, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Universal Vision's returns are expected to increase less than the market. However, during the bear market, the loss of holding Universal Vision is expected to be smaller as well. At this point, Universal Vision Bio has a negative expected return of -0.0907%. Please make sure to validate Universal Vision's standard deviation, total risk alpha, and the relationship between the coefficient of variation and jensen alpha , to decide if Universal Vision Bio performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Universal Vision Biotechnology has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly stable basic indicators, Universal Vision is not utilizing all of its potentials. The latest stock price fuss, may contribute to near-short-term losses for the sophisticated investors. ...more
| Begin Period Cash Flow | 616 M | |
| Total Cashflows From Investing Activities | -379.8 M |
Universal |
Universal Vision Relative Risk vs. Return Landscape
If you would invest 23,100 in Universal Vision Biotechnology on August 26, 2024 and sell it today you would lose (1,550) from holding Universal Vision Biotechnology or give up 6.71% of portfolio value over 90 days. Universal Vision Biotechnology is generating negative expected returns and assumes 1.9151% volatility on return distribution over the 90 days horizon. Simply put, 17% of stocks are less volatile than Universal, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Universal Vision Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Universal Vision's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Universal Vision Biotechnology, and traders can use it to determine the average amount a Universal Vision's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0474
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | 3218 |
Estimated Market Risk
| 1.92 actual daily | 17 83% of assets are more volatile |
Expected Return
| -0.09 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.05 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Universal Vision is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Universal Vision by adding Universal Vision to a well-diversified portfolio.
Universal Vision Fundamentals Growth
Universal Stock prices reflect investors' perceptions of the future prospects and financial health of Universal Vision, and Universal Vision fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Universal Stock performance.
| Return On Equity | 0.34 | |||
| Return On Asset | 0.16 | |||
| Profit Margin | 0.24 % | |||
| Operating Margin | 0.31 % | |||
| Current Valuation | 23.15 B | |||
| Shares Outstanding | 79.93 M | |||
| Price To Earning | 42.35 X | |||
| Price To Book | 9.66 X | |||
| Price To Sales | 7.07 X | |||
| Revenue | 2.63 B | |||
| EBITDA | 1.1 B | |||
| Cash And Equivalents | 1.06 B | |||
| Cash Per Share | 13.23 X | |||
| Total Debt | 10.33 M | |||
| Debt To Equity | 0.40 % | |||
| Book Value Per Share | 30.34 X | |||
| Cash Flow From Operations | 911.77 M | |||
| Earnings Per Share | 9.88 X | |||
| Total Asset | 3.75 B | |||
About Universal Vision Performance
Evaluating Universal Vision's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Universal Vision has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Universal Vision has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Universal Vision Biotechnology Co., Ltd. operates a chain of eye care clinics in Taiwan and China. Universal Vision Biotechnology Co., Ltd. was founded in 1992 and is based in Taipei, Taiwan. UNIVERSAL VISION is traded on Taiwan OTC Exchange in Taiwan.Things to note about Universal Vision Bio performance evaluation
Checking the ongoing alerts about Universal Vision for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Universal Vision Bio help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Universal Vision Bio generated a negative expected return over the last 90 days | |
| About 48.0% of the company shares are owned by insiders or employees |
- Analyzing Universal Vision's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Universal Vision's stock is overvalued or undervalued compared to its peers.
- Examining Universal Vision's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Universal Vision's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Universal Vision's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Universal Vision's stock. These opinions can provide insight into Universal Vision's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Universal Stock Analysis
When running Universal Vision's price analysis, check to measure Universal Vision's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Universal Vision is operating at the current time. Most of Universal Vision's value examination focuses on studying past and present price action to predict the probability of Universal Vision's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Universal Vision's price. Additionally, you may evaluate how the addition of Universal Vision to your portfolios can decrease your overall portfolio volatility.